Over the next few years, thousands of new positions in the biopharma and life sciences industry are expected to open up across the BioHealth Capital Region and the greater Philadelphia area known as Cellicon Valley.
Whether you are fresh out of the university or a seasoned veteran, many job seekers question whether or not they should aim for large biopharmaceutical companies, such as AstraZeneca, Pfizer or GlaxoSmithKline, or look at nimble, growth-stage companies, such as American Gene Technologies, Vita Therapeutics, or BioFactura, Inc., which is currently scaling their cGMP and Quality operations.
Since the approval of the first biosimilar drug in the United States six years ago, the market has rapidly expanded and is expected to grow to approximately $23 billion in the U.S. by 2027. And Maryland’s BioFactura anticipates it will be one of the companies at the forefront of this revolution of new medications.
BioFactura Inc. (“BioFactura”), a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast™ platform, announces an agreement with Rani Therapeutics (“Rani”) to assess its Ustekinumab Biosimilar (BFI-751) in combination with Rani’s RaniPill™ platform.
BioFactura CEO Dr. Darryl Sampey Shares his Entrepreneurial Journey at Frederick’s StartupGrind Event February 26, 2019 Dr. Darryl Sampey has been through the grind as CEO of Frederick’s BioFactura, a [….]
BioFactura Raising Series B Investment to Advance Lead Biosimilar into Phase One Dr. Jeffrey Hausfeld, BioFactura’s Chairman of the Board and Chief Medical Officer has been tasked with raising a Series [….]
Frederick Based Biosimilars Company begins GMP Manufacturing and Scales Headcount Image Credit: prweb.com/releases/2015/12/prweb13140953.htm BioFactura Inc. is a growing biotech company in Frederick, Maryland operating in an exciting and growing field. [….]